Honoring MG Awareness Month
June marks Myasthenia Gravis (MG) Awareness Month, a time dedicated to amplifying voices, deepening understanding, and advancing care for those living with this rare neuromuscular disorder. That’s why this series brings together expert insights and the latest research to shed light on the complexities of MG.
1-11 of 11
Understanding Variability in Myasthenia Gravis
NeuroFrontiersUnderstanding Variability in Myasthenia Gravis
Henry Kaminski, MD
SPOTLIGHT Registry Findings on Eculizumab and Ravulizumab in gMG
NeuroFrontiersSPOTLIGHT Registry Findings on Eculizumab and Ravulizumab in gMG
BCMA mRNA CAR-T Shows Durable Benefit in MG
NeuroFrontiersBCMA mRNA CAR-T Shows Durable Benefit in MG
RAISE Subgroup Analysis: Zilucoplan Without Prior Rescue Therapy in gMG
NeuroFrontiersRAISE Subgroup Analysis: Zilucoplan Without Prior Rescue Therapy in gMG
Symptom Control in gMG: Comparing Ravulizumab and Efgartigimod
NeuroFrontiersSymptom Control in gMG: Comparing Ravulizumab and Efgartigimod
Christopher A. Scheiner, MD, PhD
How Diagnostic Delays in gMG Impact Disease Severity, Outcomes, and Quality of Life
NeuroFrontiersHow Diagnostic Delays in gMG Impact Disease Severity, Outcomes, and Quality of Life
John A. Morren, MD, FAAN, FAANEM
- advertisement
Quality-of-Life Challenges in gMG Care: Navigating the Invisible Burden
NeuroFrontiersQuality-of-Life Challenges in gMG Care: Navigating the Invisible Burden
Maxwell H. Levy, MD
Debunking gMG Myths: Counseling Strategies That Change the Conversation
NeuroFrontiersDebunking gMG Myths: Counseling Strategies That Change the Conversation
Maxwell H. Levy, MD
Investigating Inebilizumab for Generalized Myasthenia Gravis: Results from MINT
NeuroFrontiersInvestigating Inebilizumab for Generalized Myasthenia Gravis: Results from MINT
Richard Nowak, MD, MS
Reducing the Burden of gMG with a Novel B-Cell Therapy
NeuroFrontiersReducing the Burden of gMG with a Novel B-Cell Therapy
Richard Nowak, MD, MS
Exploring IGF1R as a New Therapeutic Target in Myasthenia Gravis
NeuroFrontiersExploring IGF1R as a New Therapeutic Target in Myasthenia Gravis
- advertisement